CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

LEAF-4L7520Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug1308 LEAF-4L6715 Wiki 1.00
drug222 Assessing antibody responses, neutralizing capacity and memory B-cell function Wiki 1.00

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D013577 Syndrome NIH 0.11
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease

This is an open label phase II study of treatment with LEAF-4L7520 and LEAF-4L6715 in patients who experience severe acute respiratory distress syndrome (ARDS) and are receiving artificial respiratory support due to COVID-19. The purpose of this study is to evaluate the improvement in PaO2/FiO2 by more than 25% in two cohorts of patients treated with LEAF-4L7520 or LEAF-4L6715.

NCT04378920 COVID19 Acute Respiratory Distress Syndrome Drug: LEAF-4L6715 Drug: LEAF-4L7520
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Syndrome

Primary Outcomes

Measure: proportion of patients showing an increase of at least 25% of PaO2/FiO2 ratio

Time: 24 hours

Secondary Outcomes

Measure: proportion of patients with a PaO2/FiO2 ratio above 200 mm Hg

Time: 24, 48 and 72 hours

Measure: all cause mortality

Time: 28 days

No related HPO nodes (Using clinical trials)